Table 5. Inhibitory effects and IC₅₀ of series II peptide-like ligand binding rhNRP-1 (chemiluminescence detection).

Compound	AA2–AA3 fragment	Inhibition of NRP-1/VEGF-A165 binding [%]							IC50 [μM]
		100 μM	50 μM	25 μM	10 μM	5 μM	2.5 μM	1 μM
3	Dab–Pro	79.8 ± 0.8	76.6 ± 0.9	70.4 ± 0.5	58.6 ± 1.4	43.7 ± 0.7	31.4 ± 0.5	13.8 ± 0.3	8.9 ± 0.8 (ref. 40)
11	Dab–Hyp	78.6 ± 0.7	76.0 ± 0.6	67.3 ± 1.5	54.3 ± 2.0	36.0 ± 0.0	22.3 ± 1.5	22.5 ± 0.3	9.2 ± 0.7 a
12	Dab–Aze	78.8 ± 0.6	75.8 ± 0.3	69.1 ± 0.3	49.6 ± 4.2	30.1 ± 1.8	12.9 ± 1.4	7.7 ± 1.0	11.7 ± 1.2 b
13	Dab–ΔPro	87.1 ± 0.6	84.4 ± 0.3	78.1 ± 1.0	70.7 ± 0.3	58.0 ± 0.8	44.8 ± 0.4	29.9 ± 1.5	4.3 ± 0.2 c
14	Dab–Oic	83.0 ± 0.3	79.5 ± 0.5	77.7 ± 1.3	63.4 ± 1.9	52.3 ± 3.3	50.9 ± 3.2	37.7 ± 2.1	2.3 ± 0.2 d
15	Dab–Piz	51.8 ± 0.4	46.0 ± 0.6	34.8 ± 0.3	20.8 ± 0.6	—	—	—	80.5 ± 2.0 e
16	Dab–Tic	0.0 ± 3.2	17.2 ± 1.4	35.0 ± 1.2	31.5 ± 2.5	—	—	—	≫100

^alog IC₅₀ = –5.03 ± 0.07.

^blog IC₅₀ = –4.97 ± 0.05.

^clog IC₅₀ = –5.54 ± 0.04.

^dlog IC₅₀ = –5.65 ± 0.08.

^elog IC₅₀ = –4.09 ± 0.07. R² was between 0.92–0.98. Results are presented as the mean ± SEM.